INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $204,000 | -67.5% | 1,616 | -63.3% | 0.01% | -60.7% |
| Q2 2016 | $627,000 | +200.0% | 4,400 | +31328.6% | 0.03% | +300.0% |
| Q4 2015 | $209,000 | -3.7% | 14 | -98.4% | 0.01% | +75.0% |
| Q2 2015 | $217,000 | -4.0% | 900 | +12.5% | 0.00% | -42.9% |
| Q1 2015 | $226,000 | -68.6% | 800 | -73.7% | 0.01% | -69.6% |
| Q3 2014 | $720,000 | -12.4% | 3,044 | -12.4% | 0.02% | -39.5% |
| Q2 2014 | $822,000 | – | 3,474 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |